AbbVie buys Pharmacyclics in a deal for 21 billion USD

Noam Stiekema

AbbVie buys Pharmacyclics in a deal for 21 billion USD. The company surpassed the offer of rival Johnson & Johnson to control revolutionary therapy of cancer of the blood that will enable it to develop in the field of oncology. Under the deal, the American producer of rare medicines AbbVie will pay 261.25 USD per […]

AbbVie

AbbVieAbbVie buys Pharmacyclics in a deal for 21 billion USD. The company surpassed the offer of rival Johnson & Johnson to control revolutionary therapy of cancer of the blood that will enable it to develop in the field of oncology. Under the deal, the American producer of rare medicines AbbVie will pay 261.25 USD per share in cash and new shares of AbbVie, announced in a statement the two companies on Thursday. The price was 39% above the closing price of the shares of Pharmacyclics Inc from 24th February 2015, the day before announcing the possibility of the deal.

Acquisitions will help AbbVie to reduce its dependence on Humira, best-selling product is the company’s treatment of arthritis. Now it will be able to expand in the field of cancer therapy, one of the most promising areas of development of pharmaceuticals. AbbVie will gain control over Imbruvica, easy to use pill that costs about 100 thousand dollars a year and helps to avoid some serious side effects of chemotherapy. It has already been approved for the four different types of leukemia.

Pharmacyclics led negotiations and almost had agreed to be acquired by Johnson & Johnson. The discussed price was 250 USD per share, but AbbVie made better offer at the last minute, said a source familiar with the situation. AbbVie expects about 58% of the transaction to be paid in cash and 42% – equity, and be completed by mid-year. Its shares rose 1.1 percent to 60.27 dollars a share in New York. Since separated from Abbott Laboratories in 2013, AbbVie had not been able to finish any of тхе мега-деалс that tempt most of the drug industry.

Read this next

Institutional FX

Invast Global ramps up its offering with 10 soft commodity CFDs

Sydney-based prime-of-prime provider Invast Global has expanded its offering with the addition of ten soft commodity CFDs, which increases their index and commodity CFD offering to 35 instruments.

Retail FX

FF Simple and Smart Trades says Goodbye to CySEC authorization

The Cyprus Securities and Exchange Commission (CySEC) confirmed that it has wholly withdrawn the Cyprus Investment Firm (CIF) licenses of FF Simple and Smart Trades Investment Services Ltd.

Crypto Insider

Shining the Light in Crypto’s Dark Places

Something changed in regulators’ minds after the November crash of the FTX crypto exchange.

Executive Moves

Financial Commission Adds Sam Low to Dispute Resolution Committee

The Financial Commission (FinaCom PLC), a dispute resolution service that caters to the financial services industry, has appointed Sam Low as the newest member of its Dispute Resolution Committee (DRC).

Digital Assets, Uncategorized

De-facto owner of Bithumb exchange arrested in South Korea

South Korean prosecutors have arrested Kang Jong-Hyun, the anonymous chairman and owner of the country’s largest cryptocurrency exchange, Bithumb, on charges of embezzlement and stock manipulation.

Retail FX

Interactive Brokers volumes snap three-month losing streak

Electronic brokerage firm Interactive Brokers LLC (NASDAQ:IBKR) said its trading volumes rose in January, an indication that investor confidence in the financial markets is rebounding after having been fairly mixed over the past few months.

Digital Assets

VVF invests $5 million in Everscale, a potential Layer 2 solution for Venom blockchain

“For us, this is a strategic investment aimed at the technological development of projects and teams around technologies that we focus on and actively develop. In particular, we are talking about the Venom blockchain project and its ecosystem, which is planned to be launched soon and for which Everscale is a potential Layer 2 solution.”

Institutional FX

FXSpotStream volume ends string of declines on January rebound

Trading volumes on institutional FX platforms surged in January as traders increased their bets on central bankers’ policy with evidence mounting that inflation and economic growth are both losing momentum.

Industry News

DeFi firm Aurox launches SEC-compliant crowdfunding campaign on tZERO

“This is a great opportunity for us to raise capital from our community and the broader public on a leading fully regulated platform. We are confident that the tZERO Markets platform will provide us with the exposure and reach we need to attract a diverse investors to support our business growth.”

<